In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients. The new ...
MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate's ...
Endries International, Brillion, WI, a distributor of fasteners and related production components, has announced that MSD Partners, L.P., along with Endries management, has acquired Endries from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback